Manchester, KR; Lomas, EC; Waters, L; Dempsey, FC; Maskell, PD. The emergence of new psychoactive substance (NPS) benzodiazepines: A review. Drug Test. Analysis, 1 Jan 2018, 10 (1), 37-53. 713 kB. https://doi.org/10.1002/dta.2211 #2A
EMCDDA. New drugs in Europe, 2014, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 Jul 2015. 879 kB.
Bergstrand, MP; Helander, A; Hansson, T; Beck, O. Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays. Drug Test. Analysis, 1 Apr 2017, 9 (4), 640-645. 522 kB. https://doi.org/10.1002/dta.2003
Moosmann, B; King, LA; Auwärter, V. Designer benzodiazepines: A new challenge. World Psychiatry, 1 May 2015, 14 (2), 248-248. 49 kB. https://doi.org/10.1002/wps.20236
Huppertz, LM; Bisel, P; Westphal, F; Franz, F; Auwärter, V; Moosmann, B. Characterization of the four designer benzodiazepines clonazolam, deschloroetizolam, flubromazolam, and meclonazepam, and identification of their in vitro metabolites. Forensic Toxicol., 1 Jul 2015, 33 (2), 388–395. 870 kB. https://doi.org/10.1007/s11419-015-0277-6 #4
Moosmann, B; Auwärter, V. Designer benzodiazepines: Another class of new psychoactive substances. In New Psychoactive Substances : Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 383-410. 497 kB. https://doi.org/10.1007/164_2018_154 #Meclonazepam